Revised FIGO staging for endometrial cancer
Cancer staging is one of the fundamental activities in oncology and is of pivotal importance to the modern management of cancer patients. It is structured to represent a major prognostic factor in predicting patients' outcome and lending order to the complex dynamic behaviour of a cancer.¹ To optimally manage any malignant disease, certain factors must be taken into consideration: the site of origin of the disease, its biology, and the extent of the disease at the time of presentation, i.e. the stage of the tumour.² One of the major purposes of cancer staging, agreed upon internationally, is to offer a classifi cation of a cancer's extent in order to provide a method of conveying one's clinical experience to others for the comparison of treatment methods without ambiguity. Cancer staging is in continual evolution as diagnostic tools change and more prognostic information becomes available. In keeping with this, gynaecologic cancer staging has evolved as well. The International Federation of Gynecology and Obstetrics (FIGO) staging has a long-standing tradition and has led to easier comparisons of treatment results all over the world. However, recent developments in imaging and developments of surgical techniques such as endoscopy are diffi cult to implement by FIGO because these modalities are not readily available in less developed countries. The FIGO staging is regularly updated, based on new evidence and insight in tumour biology. The most recent adaptation of endometrium cancer staging was recently published (Table I) . 3 The rationale for the changes [4] [5] [6] that were implemented is described hereafter. In addition, changes that were proposed by the Gynecologic Cancer Intergroup, though not implemented in the new FIGO staging, are discussed. 4 
Grouping Stage IA and IB
Given the comparable outcomes for the old Stage IA and IB that are reported in the FIGO Annual Reports, both were grouped into Stage IA.
Stage II
Stage II no longer has a subset A and B. Involvement of the endocervical glandular portion of the cervix is now considered Stage I. 
Stage IIIC, inguinal lymph node involvement
There are only case reports on patients with inguinal metastases at the time of diagnosis in literature. 11, 12 Such patients may carry a rather good prognosis similar to other patients with retroperitoneal metastases. Thus, besides retroperitoneal node involvement, patients with inguinal node metastases could also be allocated to Stage IIIC disease instead of being classifi ed as Stage IVB. However, given the lack of good evidence, the FIGO committee decided to maintain allocation of inguinal node metastases to Stage IVB.
Stage IIIC, retroperitoneal lymph node involvement
It is proposed to add the statement that, although * Either G1, G2, or G3. ** Endocervical glandular involvement only should be considered as Stage I and no longer as Stage II. # Positive cytology has to be reported separately without changing the stage. lymphadenectomy 14 is not mandatory to stage all patients with endometrial cancer, it is recommended in operable high-risk clinical Stage I patients and in those with adverse histologic subtypes such as serous or clear cell carcinomas. [13] [14] [15] Lymphadenectomy seems to be particularly important in decision-making for adjuvant therapy. Lymph node-negative patients do not benefi t from adjuvant radiotherapy, whereas node-positive patients may benefi t from chemotherapy. In patients with surgically staged negative nodes, toxicity might be considerably reduced. 16 The increased awareness of paraaortic nodal involvement 17 and its clinical importance 18 results in a separate classifi cation. As a result, Stage IIIC is now categorised as IIIC1 (indicating positive pelvic nodes) and IIIC2 (indicating positive para-aortic nodes with or without positive pelvic nodes). Although the FIGO committee thus validates the importance of para-aortic node involvement, there is no defi nition of the extent and quality of lymphadenectomy. Complete para-aortic lymphadenectomy refers to the renal vessels rather than the inferior mesenteric artery as the upper border. 6 
Subdivision of Stage IVB
The prognosis of patients with peritoneal involvement is distinctly better than those with parenchymal-visceral and/or extra-abdominal metastases. 13 However, the FIGO committee maintained the old classifi cation.
Clinicians need to implement the new FIGO staging in their practice and the reason why is twofold: (1) to allow comparison of patients between centres and (2) to divide patients and their tumours into prognostic groups.
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